中国药物经济学2019，Vol.14Issue(2)：18-28,11.DOI:10.12010/j.issn.1673-5846.2019.02.004
药物经济学评价报告质量评估指南
Guidelines for Quality Assessment of Pharmacoeconomic Evaluation Report
摘要
Abstract
Pharmacoeconomics has been increasingly widely applied and drawn attention from more and more countries and regions. However, the quality of its research still exhibits many problems. Current health economic assessment scale has both advantages and disadvantages. It presents insufficient adaptability to the quality assessment for "Pharmacoeconomic Evaluation Report". Additionally, the applicability and operability of its framework and content can not fully meet the quality assessment for"Pharmacoeconomic Evaluation Report". Therefore, the successful development of the Guidelines for Quality Assessment of Pharmacoeconomic Evaluation Report plays a vital role in the standardization of Pharmacoeconomic Evaluation Report. The Guidelines for Quality Assessment of Pharmacoeconomic Evaluation Report was short for "PEERs". It was compiled by the team of Professor Zhu Wentao of Beijing University of Chinese Medicine together with experts in the industry. PEERs standardized the research process of pharmacoeconomics evaluation, and solved the problems in quality assessment for "Pharmacoeconomic Evaluation Report". PEERs include four parts: operation instructions, quality assessment scale for Pharmacoeconomic Evaluation Report, assessment methods and assessment results. The quality assessment scale for Pharmacoeconomic Evaluation Report is the main content and is mainly used to assess the quality and research process of Pharmacoeconomic Evaluation Report. The assessment results of Pharmacoeconomic Evaluation Report are divided into complete consistency, basic consistency and inconsistency. PEERs was officially released on September 26, 2018 with the official approval of the China Association of Chinese Medicine.关键词
药物经济学/评价报告/质量评估/指南Key words
Pharmacoeconomics/Evaluation report/Quality assessment/Guideline分类
医药卫生引用本文复制引用
高海亮,卢颖,姜婷婷,张聪,王煊,朱文涛..药物经济学评价报告质量评估指南[J].中国药物经济学,2019,14(2):18-28,11.基金项目
北京中医药大学发展基金(2040072220002) （2040072220002）
